Moreover, since BC cells and tumor stroma actively produce FGF ligands, the progressive loss of PTX3 and of its FGF-trap function during BC progression may impact on the cross-talk among different components of tumor microenvironment that drive proliferation, angiogenesis, immune modulation, and drug resistance [29]. The gene discussed is PTX3; the disease is breast cancer.